Christopher Filson

List of Publications by Year
in descending order

145	2,645	236833	206029
papers	citations	25 h-index	48 g-index

147	147	147	4985
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576, 465-470.	13.7	510
2	Prostate cancer detection with magnetic resonanceâ€ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer, 2016, 122, 884-892.	2.0	346
3	Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer, 2016, 122, 3075-3086.	2.0	254
4	The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer. Journal of Urology, 2016, 195, 1724-1730.	0.2	69
5	Semantics in active surveillance for men with localized prostate cancer â€" results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	1.9	65
6	Technique and Outcomes of Robot-assisted Retroperitoneoscopic Partial Nephrectomy: A Multicenter Study. European Urology, 2014, 66, 542-549.	0.9	62
7	Variation in Use of Active Surveillance among Men Undergoing Expectant Treatment for Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 75-81.	0.2	59
8	Expectant management for men with early stage prostate cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 264-282.	157.7	59
9	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
10	The Efficacy and Safety of Combined Therapy with Î±-Blockers and Anticholinergics for Men with Benign Prostatic Hyperplasia: A Meta-Analysis. Journal of Urology, 2013, 190, 2153-2160.	0.2	50
11	Patient Frailty and Discharge Disposition Following Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e615-e621.	0.9	50
12	Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access Journal of Urology, 2011, 4, 1.	0.3	48
13	Comparing performance of Morbidity and Mortality Conference and National Surgical Quality Improvement Program for detection of complications after urologic surgery. Urology, 2006, 68, 931-937.	0.5	43
14	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology, 2018, 117, 57-63.	0.5	43
15	Implementation of a Tele-urology Program for Outpatient Hematuria Referrals: Initial Results and Patient Satisfaction. Urology, 2016, 97, 33-39.	0.5	41
16	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 36-41.	0.6	41
17	Surgical Margins in Nephron-Sparing Surgery for Renal Cell Carcinoma. Current Urology Reports, 2017, 18, 8.	1.0	39
18	Trends in Medical Management of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. Urology, 2013, 82, 1386-1393.	0.5	37

#	Article	IF	Citations
19	Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics. Urology, 2018, 113, 40-44.	0.5	37
20	Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. Journal of Urology, 2018, 199, 89-97.	0.2	34
21	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 952-957.	0.8	33
22	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.2	30
23	Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. Urology, 2019, 130, 99-105.	0.5	29
24	Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e1-40.e8.	0.8	27
25	Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e19-21.e26.	0.8	26
26	Surgeon Characteristics and Long-Term Trends in the Adoption of Laparoscopic Radical Nephrectomy. Journal of Urology, 2011, 185, 2072-2077.	0.2	25
27	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
28	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 432.e1-432.e10.	0.8	23
29	Health care reform in 2010: transforming the delivery system to improve quality of care. World Journal of Urology, 2011, 29, 85-90.	1.2	22
30	Improvement in Clinical TNM Staging Documentation Within a Prostate Cancer Quality Improvement Collaborative. Urology, 2014, 83, 781-787.	0.5	21
31	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.2	19
32	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
33	Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma. Urology, 2011, 77, 825-830.e1.	0.5	17
34	Health status and use of partial nephrectomy in older adults with early-stage kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 153.e7-153.e14.	0.8	17
35	Urologist Use of Cystoscopy for Patients Presenting With Hematuria in the United States. Urology, 2017, 100, 20-26.	0.5	17
36	Surgical approach and the use of lymphadenectomy and adrenalectomy among patients undergoing radical nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 856-863.	0.8	15

#	Article	IF	Citations
37	Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 250-256.	0.8	15
38	Determinants of radical cystectomy operative time. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 431.e17-431.e24.	0.8	14
39	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian Journal of Urology, 2017, 4, 230-238.	0.5	13
40	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
41	Multiâ€institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with <scp>Plâ€RADS</scp> 3 lesions. Cancer, 2022, 128, 3287-3296.	2.0	13
42	Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. BMC Medical Informatics and Decision Making, 2019, 19, 6.	1.5	12
43	Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 493.e9-493.e15.	0.8	12
44	Patient-Reported Convalescence and Quality of Life Recovery. Surgical Innovation, 2016, 23, 598-605.	0.4	11
45	Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy. Clinical Genitourinary Cancer, 2018, 16, e705-e710.	0.9	11
46	Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries. JAMA Network Open, 2019, 2, e198956.	2.8	11
47	Expectant management of veterans with earlyâ€stage prostate cancer. Cancer, 2016, 122, 626-633.	2.0	10
48	Longâ€term consequences of the USPSTF Grade D recommendation for prostateâ€specific antigen screening. Cancer, 2020, 126, 694-696.	2.0	9
49	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e15-27.e21.	0.8	8
50	MP60-11 SHOULD A NORMAL MULTIPARAMETRIC MRI PRECLUDE PROSTATE BIOPSY?. Journal of Urology, 2015, 193, .	0.2	8
51	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
52	The importance of surgical margins in renal cell and urothelial carcinomas. Journal of Surgical Oncology, 2016, 113, 316-322.	0.8	7
53	Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. European Urology Focus, 2020, 6, 242-248.	1.6	7
54	Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. Urology Practice, 2019, 6, 93-99.	0.2	7

#	Article	IF	Citations
55	Efficacy of Percutaneous Tibial Nerve Stimulation for Overactive Bladder in Women and Men at a Safety Net Hospital. Journal of Urology, 2020, 203, 385-391.	0.2	7
56	Prospective Tracking of Pediatric Urology Consults: Knowing is Half the Battle. Journal of Urology, 2012, 187, 1844-1849.	0.2	6
57	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. Journal of Urology, 2017, 198, 1046-1053.	0.2	6
58	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. Cancer, 2018, 124, 2897-2905.	2.0	6
59	Patient Acceptance of Teleurology via Telephone vs Face-to-Face Clinic Visits for Hematuria Consultation at a Veterans Affairs Medical Center. Urology Practice, 2018, 5, 253-259.	0.2	6
60	Association Between Online Information-Seeking and Adherence to Guidelines for Breast and Prostate Cancer Screening. Preventing Chronic Disease, 2018, 15, E45.	1.7	6
61	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e15-181.e21.	0.8	6
62	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal USâ€“guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. Radiology Imaging Cancer, 2020, 2, e190078.	0.7	6
63	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer, 2021, 127, 2974-2979.	2.0	6
64	The value of new drugs for advanced prostate cancer. Cancer, 2021, 127, 3457-3465.	2.0	6
65	Logic Regression for Provider Effects on Kidney Cancer Treatment Delivery. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-9.	0.7	5
66	The Cost Burden of Complications after Major Surgery for Urological Cancer: Opportunities for Value Creation in Urology. Urology Practice, 2016, 3, 81-89.	0.2	5
67	Effect of a Prostate Cancer Screening Decision Aid for African-American Men in Primary Care Settings. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2157-2164.	1.1	5
68	Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. Urology, 2020, 142, 87-93.	0.5	5
69	Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. Clinical Genitourinary Cancer, 2019, 17, e494-e504.	0.9	4
70	Use of Office Versus Ambulatory Surgery Center Setting and Associated Ancillary Services on Healthcare Cost Burden for Vasectomy Procedures. Urology, 2019, 129, 29-34.	0.5	4
71	Survival benefit with extended lymphadenectomy for advanced renal malignancy: A population-based analysis. Asian Journal of Urology, 2020, 7, 29-36.	0.5	4
72	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. Urology Practice, 2020, 7, 138-144.	0.2	4

#	Article	IF	Citations
73	Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e2015198.	2.8	4
74	Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. Urology, 2020, 141, 101-107.	0.5	4
75	Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. Cancer Medicine, 2021, 10, 8412-8420.	1.3	4
76	In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study. British Journal of Radiology, 2018, 91, 20170603.	1.0	3
77	Palliative care use among bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e1-788.e6.	0.8	3
78	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
79	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.2	3
80	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	1.3	3
81	Quality of care and economic considerations of active surveillance of men with prostate cancer. Translational Andrology and Urology, 2018, 7, 203-213.	0.6	2
82	Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk. Cancer, 2021, 127, 203-208.	2.0	2
83	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. European Urology Open Science, 2022, 37, 80-89.	0.2	2
84	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
85	489 USE OF PARTIAL NEPHRECTOMY IN RURAL VERSUS URBAN PRACTICE SETTINGS. Journal of Urology, 2010, 183, .	0.2	1
86	1674 RISK OF COMPLICATIONS OF PERIOPERATIVE MITOMYCIN (MMC) AMONG BLADDER CANCER PATIENTS UNDERGOING ENDOSCOPIC TUMOR RESECTION. Journal of Urology, 2012, 187, .	0.2	1
87	V6-06 USE OF MRI/US FUSION FOR TARGETED PROSTATE BIOPSY IN ACTIVE SURVEILLANCE. Journal of Urology, 2014, 191, .	0.2	1
88	MP11-05 MR-US FUSION BIOPSY: IMPORTANCE OF BOTH SYSTEMATICÂAND TARGETED SAMPLING TO DIAGNOSE PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	1
89	MP78-18 THE RELATIONSHIP BETWEEN PREOPERATIVE C - REACTIVE PROTEIN AND FUHRMAN NUCLEAR GRADE IN STAGE T1 RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.2	1
90	Author Reply. Urology, 2016, 97, 38-39.	0.5	1

#	Article	IF	Citations
91	Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities. Urology, 2018, 115, 96-101.	0.5	1
92	Moving toward a more rational, evidenceâ€based approach to PSA screening, diagnosis, and treatment of prostate cancer. Cancer, 2018, 124, 2684-2686.	2.0	1
93	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. Radiology Imaging Cancer, 2019, 1, e190016.	0.7	1
94	Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. Brachytherapy, 2020, 19, 557-566.	0.2	1
95	Enhanced antibiotic prophylaxis and infection-related complications following prostate biopsy. World Journal of Urology, 2021, 39, 3415-3422.	1.2	1
96	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clinical Genitourinary Cancer, 2021, 19, e193-e199.	0.9	1
97	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. Urology Practice, 2021, 8, 576-582.	0.2	1
98	Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. Urology Practice, 2019, 6, 123-128.	0.2	1
99	Antibiotic Stewardship for Ambulatory Urological Procedures: Cystoscopy and Vasectomy. Urology Practice, 2020, 7, 272-278.	0.2	1
100	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.2	1
101	345 SHORT-TERM AND OFF-LABEL USE OF ORAL TARGETED THERAPY FOR PATIENTS WITH RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	0
102	721 SURGICAL APPROACH AND THE USE OF LYMPHADENECTOMY AND ADRENALECTOMY FOR PATIENTS WITH RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	0
103	1481 UTILIZATION OF NEPHRON-SPARING SURGERY AMONG RENAL CELL CARCINOMA PATIENTS WITH DIABETES OR HYPERTENSION. Journal of Urology, 2010, 183, .	0.2	0
104	319 PAYMENTS FOR OUTPATIENT UROLOGIC CARE IN NON-HOSPITAL-BASED SETTINGS. Journal of Urology, 2011, 185, .	0.2	0
105	40 DO SHORT-TERM OUTCOMES FOLLOWING COMMON UROLOGIC PROCEDURES VARY BY THE AMBULATORY CARE SETTING WHERE THEY WERE PERFORMED?. Journal of Urology, 2011, 185, .	0.2	0
106	143 TRENDS AND VARIATION IN MEDICAL MANAGEMENT OF MEN WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS (1993-2010). Journal of Urology, 2013, 189, .	0.2	0
107	Editorial Comment. Urology, 2013, 82, 333-334.	0.5	0
108	441 PATIENT RECOVERY AND QUALITY OF LIFE AFTER RADICAL CYSTECTOMY: COMPARISON OF OPEN VERSUS ROBOTIC APPROACHES. Journal of Urology, 2013, 189, .	0.2	0

#	Article	IF	Citations
109	MP58-15 VARIATION IN USE OF ACTIVE SURVEILLANCE AMONG MEN UNDERGOING EXPECTANT MANAGEMENT OF EARLY-STAGE PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
110	PD30-01 MR-US FUSION BIOPSY TO DIAGNOSE PROSTATE CANCER: FIRST 1000 MEN AT UCLA. Journal of Urology, 2015, 193, .	0.2	0
111	MP27-15 INTOLERANCE OF UNCERTAINTY AND URINARY SYMPTOMS PREDICT ANXIETY FOR MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
112	MP65-20 DETERMINANTS OF OPERATIVE TIME FOR BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	0
113	MP24-01 SECOND PRIMARY MALIGNANCIES: AN ANALYSIS OF SEER DATA. Journal of Urology, 2015, 193, .	0.2	0
114	Editorial Comment. Journal of Urology, 2016, 196, 1421-1421.	0.2	0
115	MP31-09 COMORBIDITY, DISABILITY, AND PARTIAL NEPHRECTOMY USE FOR OLDER PATIENTS WITH STAGE I KIDNEY CANCER. Journal of Urology, 2016, 195, .	0.2	0
116	MP31-07 TELE-UROLOGY VERSUS FACE-TO-FACE CLINICS: A SURVEY OF PATIENT PREFERENCE. Journal of Urology, 2016, 195, .	0.2	0
117	MP73-18 EXTERNAL VALIDATION OF PREOPERATIVE AST/ALT (DE-RITIS) RATIO AS A PROGNOSTIC INDICATOR IN LOCALIZED AND METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.2	0
118	Caveat Emptor â€" long-term outcomes in the GÃ¶teborg active surveillance cohort. Nature Reviews Urology, 2016, 13, 307-308.	1.9	0
119	MP37-06 DELAYED TREATMENT OF HIGH-RISK PROSTATE CANCER PATIENTS: IMPACT OF SOCIOECONOMIC BARRIERS AND USE OF ADVANCED TECHNOLOGIES. Journal of Urology, 2016, 195, .	0.2	0
120	MP37-16 UROLOGIST USE OF CYSTOSCOPY FOR PATIENTS PRESENTING WITH HEMATURIA. Journal of Urology, 2016, 195, .	0.2	0
121	Editorial Comment. Journal of Urology, 2017, 197, 625-626.	0.2	0
122	Editorial Comment. Journal of Urology, 2017, 197, 689-689.	0.2	0
123	Editorial Comment. Urology, 2017, 99, 82.	0.5	0
124	PD06-03 PERSONALIZED DECISION SUPPORT FOR LOCALIZED PROSTATE CANCER: RESULTS OF A MULTI-SITE RANDOMIZED TRIAL. Journal of Urology, 2017, 197, .	0.2	0
125	MP32-01 PROSTATE BIOPSY PAYMENTS TO AMBULATORY SURGERY CENTERS STABLE AS PHYSICIAN REIMBURSEMENT FALLS: SUMMARY OF MEDICARE REIMBURSEMENT 2012 â€“ 2014. Journal of Urology, 2017, 197, .	0.2	0
126	MP76-01 SHARP DECREASE IN PROSTATE BIOPSY INCIDENCE WITH WIDE GEOGRAPHIC VARIATION FOLLOWING TASK FORCE PROSTATE CANCER SCREENING RECOMMENDATIONS. Journal of Urology, 2017, 197, .	0.2	0

#	Article	IF	Citations
127	MP86-04 NEW-ONSET DEPRESSION AND MENTAL HEALTH-RELATED QUALITY OF LIFE FOLLOWING PROSTATE CANCER DIAGNOSIS WITHOUT TREATMENT. Journal of Urology, 2017, 197, .	0.2	0
128	PD18-03 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.2	0
129	MP69-18 A PATIENT-CENTERED PRACTICE CHANGE: FINDING THE BEST APPROACH FOR PROSTATE CANCER DECISION SUPPORT. Journal of Urology, 2017, 197, .	0.2	0
130	MP08-09 POPULATION-LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI-GUIDED PROSTATE BIOPSY. Journal of Urology, 2017, 197, .	0.2	0
131	MP21-09 PROLONGED LENGTH OF STAY NOT ASSOCIATED WITH DECREASED HOSPITAL READMISSIONS FOLLOWING UNCOMPLICATED HOSPITALIZATION AFTER RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	0
132	MP16-09 REEXAMINING THE ROLE OF EXTENDED LYMPHADENECTOMY FOR THE MANAGEMENT OF RENAL MALIGNANCY IN THE TARGETED THERAPY ERA. Journal of Urology, 2017, 197, .	0.2	0
133	Editorial Comment. Urology, 2018, 111, 84-85.	0.5	0
134	Lymphadenectomy for High-Risk Prostate Cancer Patients: What Is Going on in Georgia?. Journal of the American College of Surgeons, 2018, 227, S281-S282.	0.2	0
135	High Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in Localized and Metastatic Clear Cell Renal Cell Carcinoma. Journal of the American College of Surgeons, 2018, 227, e243.	0.2	0
136	Editorial Comment. Journal of Urology, 2018, 200, 368-368.	0.2	0
137	Editorial Comment. Journal of Urology, 2018, 200, 59-59.	0.2	0
138	Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself. Cancer, 2020, 126, 2322-2323.	2.0	0
139	Reply to What is a good medical choice?. Cancer, 2021, 127, 1935-1936.	2.0	0
140	Editorial Comment. Journal of Urology, 2021, 205, 1359-1359.	0.2	0
141	Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 58.e9-58.e9.	0.8	0
142	Collecting Duct Carcinoma and Renal Medullary Carcinoma. , 2016, , 109-123.		0
143	Editorial Comment. Journal of Urology, 2020, 203, 135-135.	0.2	0
144	Reply by Authors. Journal of Urology, 2020, 203, 391-391.	0.2	0

#	Article	IF	Citations
145	A randomized, controlled trial for transurethral treatment of bladder tumors using PlasmaButton vaporization electrode or monopolar loop electrocautery. Canadian Journal of Urology, 2019, 26, 9908-9915.	0.0	0